Clinical trial
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)…
NCT00076440 · Voyager Pharmaceutical Corporation, Industry · Completed
Key facts
| NCT number | NCT00076440 |
|---|---|
| Title | Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study |
| Official title | Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study |
| Lead sponsor | Voyager Pharmaceutical Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Leuprolide acetate |
| Enrollment | 90 |
| Start date | Dec 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jan 26, 2004 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: